NCT07443020 2026-04-07
RIOT 4B
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
Clinical Trials
10 trialsNCT07192900 2026-01-15
(RIOT 4A)
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT04862767 2024-01-31
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
Autotelicbio
Phase 1 Completed
NCT02414945 2023-01-10
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
University Health Network, Toronto
Phase 1/2 Completed
NCT02408016 2021-09-13
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02070406 2019-02-28
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT00019357 2015-04-29
Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003009 2014-05-22
Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer
University of Southern California
Phase 1 Terminated
NCT00005604 2013-02-01
Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed